BioNTech

BioNTech SE, located in Mainz, Germany, is a biotechnology company that creates active immunotherapies for the individualized treatment of disease. It's also considered as one of the the largest biotech companies in Germany. It develops mRNA-based pharmaceutical candidates such as engineered cell therapy, novel antibodies, and small molecule immunomodulators for the treatment of cancer, as well as vaccines against infectious diseases and protein replacement therapies for rare diseases.

To develop treatments for cancer and beyond, the business has coupled ground-breaking research with cutting-edge technologies to pioneer the next generation of patient-specific immunotherapies. Different modes of action, high precision targeting, potency, and efficacy have been optimized across its wide range of platform products, which include mRNA therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators. BioNTech is also creating its own cutting-edge manufacturing procedures to supplement the drug development platforms.

BioNTech is dedicated to improving people's health around the world via fundamental research and development of immunotherapies that harness the full power of the immune system to treat cancer, infectious illnesses, and other serious diseases. BioNTech collaborates together with some of the world's most prestigious pharmaceutical corporations and non-profit organizations to advance medical knowledge, therapeutic innovation, and quality of care. As driving forces, the company believes in scientific rigor, innovation, and passion. Scientists and clinicians founded BioNTech to translate knowledge into survival by combining foundational research with operational expertise.

Founded: 2008
Headquarters: Mainz, Germany
Website: https://www.biontech.com/